Insider Selling: Edwards Lifesciences (NYSE:EW) VP Sells 23,145 Shares of Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Donald Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the sale, the vice president directly owned 98,611 shares in the company, valued at approximately $8,521,962.62. This represents a 19.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW traded down $0.99 during midday trading on Wednesday, hitting $86.55. The company’s stock had a trading volume of 7,328,211 shares, compared to its average volume of 4,351,045. The stock has a market capitalization of $49.83 billion, a price-to-earnings ratio of 46.04, a PEG ratio of 2.19 and a beta of 0.87. The stock’s 50 day simple moving average is $81.62 and its 200 day simple moving average is $82.97. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $88.28. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.60 billion. During the same quarter last year, the company earned $0.64 earnings per share. The firm’s revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, research analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on EW shares. Mizuho set a $95.00 target price on shares of Edwards Lifesciences and gave the company an “outperform” rating in a research note on Monday, April 13th. Canaccord Genuity Group set a $85.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Barclays reiterated an “overweight” rating and issued a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Wolfe Research upgraded shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price for the company in a research note on Wednesday, April 1st. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $95.65.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EW. Norges Bank bought a new position in Edwards Lifesciences during the fourth quarter worth about $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Edwards Lifesciences by 278.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after purchasing an additional 4,108,270 shares during the period. Viking Global Investors LP bought a new position in Edwards Lifesciences during the third quarter worth about $238,688,000. Marshall Wace LLP lifted its stake in Edwards Lifesciences by 66.1% during the fourth quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock worth $505,160,000 after purchasing an additional 2,359,128 shares during the period. Finally, Bank of America Corp DE lifted its stake in Edwards Lifesciences by 132.4% during the first quarter. Bank of America Corp DE now owns 3,883,419 shares of the medical research company’s stock worth $310,984,000 after purchasing an additional 2,212,208 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.